Fibrinogen, a possible key player in Alzheimer's disease

Journal of Thrombosis and Haemostasis

Volumn 7, Issue SUPPL. 1, 2009, Pages 146-150

  Cortes Canteli, M ^a   Strickland, Sidney ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; Blood brain barrier; Fibrinogen; Neurovascular damage

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; ANCROD; FIBRIN; FIBRINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; BLOOD CLOTTING DISORDER; BRAIN BLOOD FLOW; BRAIN BLOOD VESSEL; BRAIN PERFUSION; CEREBROVASCULAR DISEASE; DEMENTIA; DRUG TARGETING; FIBRIN DEPOSITION; GENE EXPRESSION; GENE FUNCTION; HEMOSTASIS; HUMAN; INFLAMMATION; MICROVASCULATURE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; REVIEW;

ALZHEIMER DISEASE; CEREBROVASCULAR DISORDERS; FIBRINOGEN; HUMANS; INFLAMMATION;

EID: 67849133379     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2009.03376.x     Document Type: Review

References (65)

1. Cummings JL, Cole G. Alzheimer disease. JAMA 2002; 287: 2335-8.
2. Roberson ED, Mucke L. 100years and counting: Prospects for defeating Alzheimer's disease. Science 2006; 314: 781-4.
3. Dawbarn D, Allen SJ. Neurobiology of Alzheimer's Disease: (Molecular and Cellular Neurobiology), 3rd edn. Oxford, New York: Oxford University Press, 2007.
4. Carlsson CM. Lessons learned from failed and discontinued clinical trials for the treatment of Alzheimer's disease: Future directions. J Alzheimers Dis 2008; 15: 327-38.
5. Doraiswamy PM, Xiong GL. Pharmacological strategies for the prevention of Alzheimer's disease. Expert Opin Pharmacother 2006; 7: 1-10.
6. Farkas E, Luiten PG. Cerebral microvascular pathology in aging and Alzheimer's disease. Prog Neurobiol 2001; 64: 575-611.
7. Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat Rev Neurosci 2004; 5: 347-60.
8. de la Torre JC. Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol 2004; 3: 184-90.
9. Thal DR, Griffin WS, Braak H. Parenchymal and vascular Abeta-deposition and its effects on the degeneration of neurons and cognition in Alzheimer's disease. J Cell Mol Med 2008; 12: 1848-62.
10. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297: 353-6.
11. Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F, Guido T, Hagopian S, Johnson-Wood K, Khan K, Lee M, Leibowitz P, Lieberburg I, Little S, Masliah E, McConlogue L. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 1995; 373: 523-7.
12. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996; 274: 99-102.
13. Chishti MA, Yang DS, Janus C, Phinney AL, Horne P, Pearson J, Strome R, Zuker N, Loukides J, French J, Turner S, Lozza G, Grilli M, Kunicki S, Morissette C, Paquette J, Gervais F, Bergeron C, Fraser PE, Carlson GA, et al. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J Biol Chem 2001; 276: 21562-70.
14. Lemere CA, Maier M, Jiang L, Peng Y, Seabrook TJ. Amyloid-beta immunotherapy for the prevention and treatment of Alzheimer disease: lessons from mice, monkeys, and humans. Rejuvenation Res 2006; 9: 77-84.
15. Nitsch RM, Hock C. Targeting beta-amyloid pathology in Alzheimer's disease with Abeta immunotherapy. Neurotherapeutics 2008; 5: 415-20.
16. Vasilevko V, Cribbs DH. Novel approaches for immunotherapeutic intervention in Alzheimer's disease. Neurochem Int 2006; 49: 113-26.
17. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 2007; 8: 101-12.
18. Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev 2005; 57: 173-85.
19. Niwa K, Kazama K, Younkin L, Younkin SG, Carlson GA, Iadecola C. Cerebrovascular autoregulation is profoundly impaired in mice overexpressing amyloid precursor protein. Am J Physiol Heart Circ Physiol 2002; 283: H315-23.
20. Niwa K, Kazama K, Younkin SG, Carlson GA, Iadecola C. Alterations in cerebral blood flow and glucose utilization in mice overexpressing the amyloid precursor protein. Neurobiol Dis 2002; 9: 61-8.
21. Iadecola C, Gorelick PB. Converging pathogenic mechanisms in vascular and neurodegenerative dementia. Stroke 2003; 34: 335-7.
22. Grammas P, Reimann-Philipp U, Weigel PH. Cerebrovasculature-mediated neuronal cell death. Ann N Y Acad Sci 2000; 903: 55-60.
23. Brun A, Englund E. A white matter disorder in dementia of the Alzheimer type: A pathoanatomical study. Ann Neurol 1986; 19: 253-62.
24. Wen Y, Yang S, Liu R, Simpkins JW. Transient cerebral ischemia induces site-specific hyperphosphorylation of tau protein. Brain Res 2004; 1022: 30-8.
25. Vinters HV, Wang ZZ, Secor DL. Brain parenchymal and microvascular amyloid in Alzheimer's disease. Brain Pathol 1996; 6: 179-95.
26. Viswanathan A, Rocca WA, Tzourio C. Vascular risk factors and dementia: How to move forward? Neurology 2009; 72: 368-74.
27. Mielke MM, Rosenberg PB, Tschanz J, Cook L, Corcoran C, Hayden KM, Norton M, Rabins PV, Green RC, Welsh-Bohmer KA, Breitner JC, Munger R, Lyketsos CG. Vascular factors predict rate of progression in Alzheimer disease. Neurology 2007; 69: 1850-8.
28. Breteler MM. Vascular involvement in cognitive decline and dementia. Epidemiologic evidence from the Rotterdam Study and the Rotterdam Scan Study. Ann N Y Acad Sci 2000; 903: 457-65.
29. Roher AE, Esh C, Kokjohn TA, Kalback W, Luehrs DC, Seward JD, Sue LI, Beach TG. Circle of willis atherosclerosis is a risk factor for sporadic Alzheimer's disease. Arterioscler Thromb Vasc Biol 2003; 23: 2055-62.
30. Honig LS, Tang MX, Albert S, Costa R, Luchsinger J, Manly J, Stern Y, Mayeux R. Stroke and the risk of Alzheimer disease. Arch Neurol 2003; 60: 1707-12.
31. de la Torre JC. How do heart disease and stroke become risk factors for Alzheimer's disease? Neurol Res 2006; 28: 637-44.
32. de la Torre JC. Alzheimer disease as a vascular disorder: Nosological evidence. Stroke 2002; 33: 1152-62.
33. Luchsinger JA, Reitz C, Honig LS, Tang MX, Shea S, Mayeux R. Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology 2005; 65: 545-51.
34. Rensink AA, de Waal RM, Kremer B, Verbeek MM. Pathogenesis of cerebral amyloid angiopathy. Brain Res Brain Res Rev 2003; 43: 207-23.
35. Nicoll JA, Yamada M, Frackowiak J, Mazur-Kolecka B, Weller RO. Cerebral amyloid angiopathy plays a direct role in the pathogenesis of Alzheimer's disease. Pro-CAA position statement. Neurobiol Aging 2004; 25: 589-97.
36. Wolozin B, Maheshwari S, Jones C, Dukoff R, Wallace W, Racchi M, Nagula S, Shulman NR, Sunderland T, Bush A. Beta-amyloid augments platelet aggregation: Reduced activity of familial angiopathy-associated mutants. Mol Psychiatry 1998; 3: 500-7.
37. Kowalska MA, Badellino K. beta-Amyloid protein induces platelet aggregation and supports platelet adhesion. Biochem Biophys Res Commun 1994; 205: 1829-35.
38. Lim GP, Yang F, Chu T, Chen P, Beech W, Teter B, Tran T, Ubeda O, Ashe KH, Frautschy SA, Cole GM. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci 2000; 20: 5709-14.
39. Zhou Y, Su Y, Li B, Liu F, Ryder JW, Wu X, Gonzalez-DeWhitt PA, Gelfanova V, Hale JE, May PC, Paul SM, Ni B. Nonsteroidal anti-inflammatory drugs can lower amyloidogenic Abeta42 by inhibiting Rho. Science 2003; 302: 1215-7.
40. Mari D, Parnetti L, Coppola R, Bottasso B, Reboldi GP, Senin U, Mannucci PM. Hemostasis abnormalities in patients with vascular dementia and Alzheimer's disease. Thromb Haemost 1996; 75: 216-8.
41. Gupta A, Watkins A, Thomas P, Majer R, Habubi N, Morris G, Pansari K. Coagulation and inflammatory markers in Alzheimer's and vascular dementia. Int J Clin Pract 2005; 59: 52-7.
42. Grammas P, Samany PG, Thirumangalakudi L. Thrombin and inflammatory proteins are elevated in Alzheimer's disease microvessels: Implications for disease pathogenesis. J Alzheimers Dis 2006; 9: 51-8.
43. Barber M, Tait RC, Scott J, Rumley A, Lowe GD, Stott DJ. Dementia in subjects with atrial fibrillation: Hemostatic function and the role of anticoagulation. J Thromb Haemost 2004; 2: 1873-8.
44. Weisel JW. Fibrinogen and fibrin. Adv Protein Chem 2005; 70: 247-99.
45. Ujiie M, Dickstein DL, Carlow DA, Jefferies WA. Blood-brain barrier permeability precedes senile plaque formation in an Alzheimer disease model. Microcirculation 2003; 10: 463-70.
46. Kumar-Singh S, Pirici D, McGowan E, Serneels S, Ceuterick C, Hardy J, Duff K, Dickson D, Van Broeckhoven C. Dense-core plaques in Tg2576 and PSAPP mouse models of Alzheimer's disease are centered on vessel walls. Am J Pathol 2005; 167: 527-43.
47. Paul J, Strickland S, Melchor JP. Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimer's disease. J Exp Med 2007; 204: 1999-2008.
48. Kalaria RN. The blood-brain barrier and cerebrovascular pathology in Alzheimer's disease. Ann N Y Acad Sci 1999; 893: 113-25.
49. Bowman GL, Kaye JA, Moore M, Waichunas D, Carlson NE, Quinn JF. Blood-brain barrier impairment in Alzheimer disease: Stability and functional significance. Neurology 2007; 68: 1809-14.
50. Zipser BD, Johanson CE, Gonzalez L, Berzin TM, Tavares R, Hulette CM, Vitek MP, Hovanesian V, Stopa EG. Microvascular injury and blood-brain barrier leakage in Alzheimer's disease. Neurobiol Aging 2007; 28: 977-86.
51. Fiala M, Liu QN, Sayre J, Pop V, Brahmandam V, Graves MC, Vinters HV. Cyclooxygenase-2-positive macrophages infiltrate the Alzheimer's disease brain and damage the blood-brain barrier. Eur J Clin Invest 2002; 32: 360-71.
52. Ryu JK, McLarnon JG. A leaky blood-brain barrier, fibrinogen infiltration and microglial reactivity in inflamed Alzheimer's disease brain. J Cell Mol Med 2008. Epub ahead of print. PMID:18657226.
53. van Oijen M, Witteman JC, Hofman A, Koudstaal PJ, Breteler MM. Fibrinogen is associated with an increased risk of Alzheimer disease and vascular dementia. Stroke 2005; 36: 2637-41.
54. Lee JW, Namkoong H, Kim HK, Kim S, Hwang DW, Na HR, Ha SA, Kim JR, Kim JW. Fibrinogen gamma-A chain precursor in CSF: A candidate biomarker for Alzheimer's disease. BMC Neurol 2007; 7: 14.
55. Xu G, Zhang H, Zhang S, Fan X, Liu X. Plasma fibrinogen is associated with cognitive decline and risk for dementia in patients with mild cognitive impairment. Int J Clin Pract 2008; 62: 1070-5.
56. Ledesma MD, Da Silva JS, Crassaerts K, Delacourte A, De Strooper B, Dotti CG. Brain plasmin enhances APP alpha-cleavage and Abeta degradation and is reduced in Alzheimer's disease brains. EMBO Rep 2000; 1: 530-5.
57. Melchor JP, Pawlak R, Strickland S. The tissue plasminogen activator-plasminogen proteolytic cascade accelerates amyloid-beta (Abeta) degradation and inhibits Abeta-induced neurodegeneration. J Neurosci 2003; 23: 8867-71.
58. Sutton R, Keohane ME, VanderBerg SR, Gonias SL. Plasminogen activator inhibitor-1 in the cerebrospinal fluid as an index of neurological disease. Blood Coagul Fibrinolysis 1994; 5: 167-71.
59. Bugge TH, Kombrinck KW, Flick MJ, Daugherty CC, Danton MJ, Degen JL. Loss of fibrinogen rescues mice from the pleiotropic effects of plasminogen deficiency. Cell 1996; 87: 709-19.
60. Adams RA, Passino M, Sachs BD, Nuriel T, Akassoglou K. Fibrin mechanisms and functions in nervous system pathology. Mol Interv 2004; 4: 163-76.
61. Suh TT, Holmback K, Jensen NJ, Daugherty CC, Small K, Simon DI, Potter S, Degen JL. Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-deficient mice. Genes Dev 1995; 9: 2020-33.
62. Bell WR, Shapiro SS, Martinez J, Nossel HL. The effects of ancrod, the coagulating enzyme from the venom of Malayan pit viper (A. rhodostoma) on prothrombin and fibrinogen metabolism and fibrinopeptide A release in man. J Lab Clin Med 1978; 91: 592-604.
63. Burkhart W, Smith GF, Su JL, Parikh I, LeVine H III. Amino acid sequence determination of ancrod, the thrombin-like alpha-fibrinogenase from the venom of Akistrodon rhodostoma. FEBS Lett 1992; 297: 297-301.
64. Ploplis VA, Carmeliet P, Vazirzadeh S, Van Vlaenderen I, Moons L, Plow EF, Collen D. Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice. Circulation 1995; 92: 2585-93.
65. Bugge TH, Flick MJ, Daugherty CC, Degen JL. Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. Genes Dev 1995; 9: 794-807.